1374582-29-2

Upstream product

• 81028-12-8 (4S,5R)-4-benzyloxymethyl-2,2-dimethyl-1,3-dioxolane-5-carboxaldehyde 
• 78469-77-9 (4S,5S)-4-benzyloxymethyl-5-hydroxymethyl-2,2-dimethyl-1,3-dioxolane 

Downstream Products

• 1374582-32-7 (4S,5S)-5-[2-benzyloxy-(S)-1-hydroxyethyl]-4-[(E)-1-propenyl]-4,5-dihydro-2(3H)-furanone 
• 1374582-33-8 (4R,5S)-5-[2-benzyloxy-(S)-1-hydroxyethyl]-4-[(E)-1-propenyl]-4,5-dihydro-2(3H)-furanone 
• 1374582-34-9 methyl (S)-3-[3-benzyloxy-(1S,2S)-1,2-(isopropylidenedioxy)propyl]hex-4-enoate 
• 1374582-35-0 methyl (R)-3-[3-benzyloxy-(1S,2S)-1,2-(isopropylidenedioxy)propyl]hex-4-enoate 

Relevant academic research and scientific papers

Control of diastereoselectivity in orthoester Johnson-Claisen rearrangement of tartrate-based allyl alcohol: An efficient synthesis of arundic acid, a potential therapeutic agent for Alzheimer's disease

A diastereoselective orthoester Johnson-Claisen rearrangement has been employed in the synthesis of both enantiomers of arundic acid, a potential therapeutic agent against Alzheimer's disease. The effect of solvent, olefin geometry and alcohol chirality on the diastereoselectivity of the orthoester Johnson-Claisen rearrangement of a tartrate-based allyl alcohol has been studied. A diastereoselective orthoester Johnson-Claisen rearrangement has been employed in the synthesis of both enantiomers of arundic acid, a potential therapeutic agent for Alzheimer's disease. The effect of solvent, olefin geometry and alcohol chirality on the diastereoselectivity of the orthoester Johnson-Claisen rearrangement ofa tartrate-based allyl alcohol has beenstudied. Copyright